-- BioAge Labs (BIOA) 周二表示，其试验性药物 BGE-102 在一项针对肥胖患者的 1 期临床试验中，展现出“同类最佳”的炎症生物标志物降低效果。 该公司称，每日 60 毫克和 120 毫克的剂量均能将高敏 C 反应蛋白水平降低至少 85%，同时保持良好的安全性。 该公司计划于今年上半年启动一项专注于心血管风险的 2 期临床试验，预计将于年底前获得初步数据。 BioAge 还计划于 2026 年年中启动一项针对糖尿病性黄斑水肿的概念验证试验，以评估该疗法对视网膜疾病的疗效。 该公司股价在周二盘前交易中上涨了 9%。
Price: $20.49, Change: $+1.69, Percent Change: +8.99%
Solvar (ASX:SVR) said that the Federal Court of Australia ordered the firm's unit Money3 Loans to pay a pecuniary penalty in the sum of nearly AU$1.6 million, according to a Monday Australian bourse filing.The court's decision was in relation to the penalty payable for the contraventions of the National Consumer Credit Act during the period from 2019 to 2021."Since the period in question, Money3 has invested further in its governance, complaints, hardship, and underwriting practices," Solvar Chief Executive Scott Baldwin said.
Hangzhou Changchuan Technology (SHE:300604) posted first-quarter attributable net profit of 352.5 million yuan, up 218% from 111.0 million yuan the previous year.Earnings per share rose to 0.5472 yuan from 0.1756 yuan, according to a weekend filing with the Shenzhen bourse.Operating revenue rose 69% year over year to 1.38 billion yuan from 815.3 million yuan.Shares of the semiconductor test equipment company rose 3% in recent trade.
Dawning Information Industry's (SHA:603019) net profit attributable to shareholders in the first quarter jumped 22% to 227.8 million yuan, or 0.156 yuan per share, according to a Saturday filing on the Shanghai bourse.The supercomputer manufacturer's shares rose 2% in morning trade on Monday.Operating revenue rose 24% to 3.20 billion yuan from 2.59 billion yuan in the prior year.